Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 28;7:12381. doi: 10.1038/s41598-017-12670-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Combination therapy with the 5-FU patch and systemic chemotherapy. (a) Subcutaneous models were constructed using BXPC3-luc cells. Mice were subjected to combination treatment with the 5-FU patch and gemcitabine (50 mg/kg, IP injection, once per week). The effect of combination therapy was superior to that of single agent treatment (n = 4, *p < 0.05, **p < 0.01). (b) Survival rate of mice in various treatment groups. A tumour volume of 300 mm³ was defined as the ethical end point and the survival was presented. (n = 4) (c). No differences in body weight were observed between the four groups (***p > 0.05). (d) Tumour growth was monitored with the IVIS after tumour transplantation. The bioluminescence signal was lowest in the combination therapy group. (e) Images of hematoxylin and eosin (H&E)-stained cancer tissue sections from various treatment groups, along with Ki-67 and TUNEL staining (Tunel;green, DAPI;blue) for each condition.